AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC649128.
Description: panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
Study NCT03493945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: 600 mg orally twice daily (1200 MG total)
Study NCT01391117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo.
Description: panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
Study NCT02678611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basis 250
Study NCT02678611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Basis 500
Study NCT02678611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02705417 — intervention group
Intervention type: PROCEDURE
Intervention: preoperative color Doppler ultrasonographic vascular mapping
Description: Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
Study NCT05868798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammonia Inhalant
Description: For all AI trials, a capsule containing 0.3 mL of AI (composed of 15% of ammonia and 35% of alcohol) was used according to the manufacturer's instructions (Dynarex Corporation, Orangeburg, NY). When the ammonia fumes were released, researcher immediately held the capsule under the participant's nose to inhale until a voluntary withdrawal reflex was observed.
Study NCT01193556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade TnA
Description: The PEAK PlasmaBlade will be used for the tonsillectomy.
Study NCT01193556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Traditional electrosurgery for the tonsillectomy.
Study NCT02705417 — intervention group
Intervention type: PROCEDURE
Intervention: physical examination
Description: Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
Study NCT02323191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
Study NCT02323191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
Study NCT02705417 — intervention group
Intervention type: PROCEDURE
Intervention: medical history
Description: medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
Study NCT02705417 — intervention group
Intervention type: PROCEDURE
Intervention: native arteriovenous fistula construction
Description: surgigal creation of native arterial and venous anastomoses
Study NCT02705417 — intervention group
Intervention type: PROCEDURE
Intervention: arteriovenous graft placement
Description: surgical placement of arteriovenous graft
Study NCT01689922 — intervention group
Intervention type: OTHER
Intervention: AlterG
Description: All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
Study NCT01062022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
Study NCT01062022 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FOCUS-CI
Description: Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
Study NCT01167946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone sodium succinate
Description: Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Study NCT01167946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Study NCT01167946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone sodium succinate
Description: Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
Study NCT03145142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical cord milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
Study NCT03145142 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Cord Clamping
Description: At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
Study NCT02638558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written + oral explanation
Study NCT02638558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: written explanation
Study NCT04273464 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brava-group
Description: Breast reconstruction by external tissue expansion and multiple fat transplantations(Brava group); Breast reconstruction with microsurgical DIEP-flap transfer.
Study NCT04273464 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DIEP-group
Description: Microsurgical reconstruction by DIEPO method
Study NCT04558476 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: 2 units of convalescent plasma
Study NCT04558476 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Gold Standards
Study NCT00780962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Description: Experimental:~* Before CT: 3 g NAC IV in 500 cc of 0.9% Sodium-chloride~* After CT: 200 mg NAC/hour in 0.9% Sodium-chloride at 67 cc/hour for up to 24 hours.
Study NCT00780962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Placebo:~* Before CT: 500 cc 0.9% Sodium-chloride~* After CT: NS at 67 cc/hour for up to 24 hours.
Study NCT03755063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy apps
Description: Speech therapy apps loaded on tablets
Study NCT01563250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Point of Care testing
Description: The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.~Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.~All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well.
Study NCT03286140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early endovenous ablation
Study NCT03286140 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed endovenous intervention
Study NCT01192594 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in all modules including MAPP Recovery Model
Description: 50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
Study NCT01192594 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training in all modules except MAPP Recovery Model
Description: 50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
Study NCT03280355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing training
Description: Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.~Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology.
Study NCT03280355 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Training
Description: Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.~The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.~Physical Training is conducted by the local physiotherapists in the local health centres.
Study NCT05016102 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise type
Description: Aerobic exercise and Resistance exercise
Study NCT04606238 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: Oncologists and patients will use the decision aid in the same situation (change of treatment needs to be discussed with the patient - either because of disease progression or treatment toxicity or other reasons (e.g. change of care setting).
Study NCT01313572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug
Study NCT01313572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apadenoson SPECT-MPI
Description: Apadenoson single bolus IV injection 100 or 150 ug
Study NCT01313572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
Study NCT01313572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine SPECT-MPI
Description: Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
Study NCT01196871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Migalastat HCl
Description: Oral capsules, single dose
Study NCT01196871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Beta
Description: IV infusion, single dose
Study NCT01196871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase Alfa
Description: IV infusion, single dose
Study NCT01527916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo Comparator
Study NCT01527916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Active Comparator
Study NCT01527916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-126
Description: low dose, middle dose, high dose
Study NCT03678181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Resources
Description: The investigators will provide a HIV-related content as the attention-control condition.
Study NCT03678181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Resources
Description: The investigators will provide a HIV-related content as the attention-control condition.
Study NCT03678181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: The investigators will provide evidence-based answers to users' health questions, including linkage to care.
Study NCT03678181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Testing
Description: The investigators will provide opportunities for participants to get tested through HIV home test kits.
Study NCT03678181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Testing
Description: The investigators will provide opportunities for participants to get tested through HIV home test kits.
Study NCT01079234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) once daily
Study NCT01550354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of propofol
Description: intravenous administration of propofol 2 mg/kg before intubation
Study NCT01550354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of alfentanil
Description: intravenous administration of alfentanil 14 μg/kg before intubation
Study NCT01550354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: administration of rocuronium
Description: Intravenous administration of rocuronium 0.3 mg/kg before intubation
Study NCT02791009 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular Magnetic Resonance Imaging (CMRI)
Description: CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
Study NCT03253601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strategy Training
Description: Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
Study NCT03253601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategy Training
Description: Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
Study NCT00713830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT01079234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine injected subcutaneously (under the skin) once daily
Study NCT00713830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.
Study NCT01079234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: At least three daily doses at meal-time
Study NCT00713830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector
Study NCT00713830 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pen auto-injector
Study NCT01079234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: At least three daily doses at meal-time
Study NCT03873051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenge-Focused Program
Description: Participants receiving the Challenge-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, team-based physical activity games/activities, and team-based goal-setting and behavioral skills training. Among participants with high autonomous motivation, those receiving the Challenge-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Rewards-Focused intervention.
Study NCT03873051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rewards-Focused Program
Description: Participants receiving the Rewards-Focused intervention will complete an 8-week group program. Group sessions meet once per week for 90 minutes and include three components - discussion-based health promotion initiative, group-based walking program, and individual-based goal-setting and behavioral skills training with partner-based contracts and financial incentives. Among participants with high controlled motivation, those receiving the Rewards-focused intervention are expected to show greater improvement from baseline to post- in total PA than those receiving the Challenge-Focused intervention.
Study NCT03001895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT
Description: 18F-DCFPyL PET/CT
Study NCT00713830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylurea
Description: Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
Study NCT00713830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
Study NCT00713830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
Study NCT00713830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin if given to be continued at stable dose (at least 1.5 gram per day \[except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea\]) up to the end of treatment.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, one subcutaneous injection.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dupilumab)
Description: Solution for injection, one subcutaneous injection.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol combination therapy
Description: Oral inhalation twice daily.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone/Salmeterol combination therapy
Description: Oral inhalation twice daily.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone monotherapy
Description: Oral inhalation twice daily.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone monotherapy
Description: Oral inhalation twice daily.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Oral inhalation as needed.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: Oral inhalation as needed.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Description: Oral inhalation as needed.
Study NCT01312961 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol
Description: Oral inhalation as needed.
Study NCT03511482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myAsthma Application
Description: myAsthma Application is a Multi facetted online self management tool developed by my mhealth Ltd, which is an online interface for patient to feedback symptoms and (Quality of Life) QoL score. The app consists of an online action /self management plan, Patient education videos, medication diary, Peak Flow diary, Inhaler technique videos, mindfulness videos as well as weather and Pollution forecasters.